Anita Turk, MD, details her biggest takeaways from the 2025 ASCO Annual Meeting in gastrointestinal cancers. Anita Turk, MD, medical oncologist at IU Health, discusses her biggest takeaways in the ...

Among 26 evaluable patients with clear cell ovarian or endometrial cancer, the objective response rate with the regimen was ...

Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer ...

All attendees shared a vested interest in the rapidly evolving cancer treatment landscape. Nowhere was the vastness of that ...

Operator: Good afternoon, and welcome to the Aethlon Medical Fourth Quarter Fiscal 2025 Earnings and Corporate Update ...

Opdivo/Yervoy has been approved since 2018 as first-line treatment for patients with intermediate- and poor-risk advanced RCC, and BMS was hoping to extend the use of the regimen into patients ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...